News
Wed, 01 Feb 2023 05:15:00 -0500
Wed, 01 Feb 2023 05:15:00 -0500
Financial report for the period 1 January 2022 to 31 December 2022
|
PROFIT AND LOSS |
2022 |
2021 |
Growth as reported |
Growth at CER* |
|
USD million |
|
|
|
|
|
Net sales |
25,011 |
22,395 |
26% |
16% |
|
Operating profit |
10,574 |
9,328 |
28% |
15% |
|
|
|
|
|
|
|
Net profit |
7,848 |
7,596 |
16% |
N/A |
|
Diluted earnings per share (in USD) |
3.45 |
3.3 |
18% |
N/A |
|
* CER: Constant exchange rates (average 2021). |
|
|
|
|
Lars Fruergaard Jørgensen, president and CEO: "We are very pleased with the double-digit sales growth in 2022 driven by our innovative GLP-1-based diabetes and obesity treatments, and more than 36 million people living with diabetes are now benefiting from our treatments. We continued to make progress on our Strategic aspirations and in 2023, we will continue our focus on strong commercial execution, expanding and progressing our innovative pipeline and investing significantly in the expansion of production capacity for current and future portfolio."
On 1 February 2023 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.